Newsroom

iX Biopharma has published a corporate presentation as an update to Shareholders.

Download the Letter to Shareholders here.

Download the Presentation Slides here (English) or here (Chinese).

Watch the Video Presentation here (English) or here (Chinese).

iX Biopharma has announced the development of it’s semaglutide sublingual wafer, iXB 401, targeting diabetes and obesity markets

More information can be found here.

iX Biopharma Ltd. has announced the unveiling of its novel NAD wafers at the Centre for Healthy Longevity Conference 2024

More information can be found here.

iX Biopharma Ltd. has announced the termination of the Wafermine Licensing Agreement.

More information can be found here.

iX Biopharma Ltd. has reported its first half results for the financial year as of 31 December 2023.

More information can be found here.

The responses to questions from the Securities Investors Association (Singapore) can be found here.

Questions and answers provided by iX Biopharma Ltd ahead of the upcoming AGM to be held on 13 October 2023 can be found here.

iX Biopharma Ltd. introduces MeltMed, a new wellness brand in the United States.

The news release can be found here.

The Annual General Meeting (“AGM”) of iX Biopharma Ltd will be held at 2 Science Park Drive, Ascent Main Lobby, The Metro, Singapore 118222 on Friday, 13 October 2023 at 10am.

Shareholders may access the following documents here:

Annual Report 2023
Sustainability Report 2023
Notice of AGM
Proxy form

Email address for submission of Proxy Form: agm@ixbiopharma.com

Shareholders who wish to submit questions may do so by email to agm@ixbiopharma.com

iX Biopharma Ltd. has reported its second half and full year results for the financial year ended 30 June 2023.

The financial statements for the period can be found here. 

The press release can be found here.

iX Biopharma Ltd. wishes to announce a change of registered office address.

More information can be found here. 

iX Biopharma Ltd is pleased to announce its latest development programme, IXB-322, a novel low-dose interferon wafer to be delivered sublingually for the prevention and treatment of respiratory viral illnesses, including COVID-19, influenza and respiratory syncytial virus (“RSV”).

More information can be found in the attached press release. 

Proposed issuance of convertible bonds of an aggregate principal amount of S$2,000,000 – Completion.

More information can be found here.

Proposed issuance of convertible bonds of an aggregate principal amount of S$2,000,000 – Receipt of listing and quotation notice from the Singapore Exchange Securities Trading Limited.

More information can be found here.

Proposed issuance of convertible bonds of an aggregate principal amount of S$2,000,000.

More information can be found here.

iX Biopharma Ltd. has reported its first half results for the financial year ended 31 December 2022.

The financial statements for the period can be found here.

iX Biopharma Ltd is pleased to announce the successful completion of a Phase 1 pharmacokinetic clinical study on the sublingual dexmedetomidine wafer being developed by the Company. The drug is being developed for the treatment of dementia-related agitation, which is an unmet medical need with no drug treatment approved to-date.

More information can be found in the attached press release.

The Board of Directors of iX Biopharma Ltd refers to its announcement dated 7 November 2022 and wishes to announce the reconstitution of the Board Committees of the Company with immediate effect.

More information can be found here.

The Board of Directors of iX Biopharma Ltd wishes to announce the appointment of Mr Teo Woon Keng John as an Independent Non-Executive Director of the Company and as a member of the Audit Committee, Nominating Committee and Remuneration Committee of the Company with effect from 7 November 2022. The Board considers Mr Teo Woon Keng John to be independent for the purposes of Catalist Rule 704(7) of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist.

More information can be found here.

iX Biopharma Ltd  is pleased to announce that its novel sublingual medicinal cannabidiol (“CBD”) wafer, Xativa™, has won the “Best CBD (Sublingual) Edible” award” at the 2022 World CBD Awards ceremony in Barcelona, Spain.

The awards ceremony is a highlight of the World CBD B2B Expo and Conference, and celebrates the best-in-class in the CBD and Hemp industry for their standards, excellence, and achievements by recognising companies that go the extra mile to make the industry a safe and respected place, and operate their business with integrity, transparency and ethics. Products nominated for the awards undergo a rigorous judging process employing lab report results, research panel reports, physical testing, application, and supporting documents as well as an aesthetics and safety report. The benchmarks are thoroughly examined by and independent panel of qualified and respected scientists, physicians, and professionals who are experts in the CBD or Hemp industry.

More information can be found in the attached press release.

The Board of Directors of iX Biopharma Ltd. is pleased to announce that at the Annual General Meeting (AGM) of the Company held on 14 October 2022, all resolutions set out in the Notice of AGM dated 22 September 2022 were duly passed by way of a poll vote.

The results of AGM can be found at this link.

A Corporate Update was also presented at the end of the AGM. The presentation slides are available here.

iX Biopharma wishes to address questions received from the Shareholders ahead of the upcoming annual general meeting to be held on 14 October 2022.

The questions and answers can be viewed at this link.

In line with the advisory by Singapore Exchange Regulation for live engagement and live voting, and with the return to normalcy of the COVID-19 situation, the Company’s forthcoming Annual General meeting (“AGM”) will be held at NUSS Kent Ridge Guild House, Inner Chamber, 9 Kent Ridge Drive, Singapore 119241.

Shareholders may access the following documents here:

Annual Report 2022
Sustainability Report 2022
Notice of AGM
AGM Proxy form

Email address for submission of AGM Proxy Form: agm@ixbiopharma.com

Shareholders who wish to submit questions may do so by email to agm@ixbiopharma.com

iX Biopharma Ltd is pleased to announce an expansion of its pipeline with the launch of a programme to develop a sublingual dexmedetomidine wafer for the treatment of agitation in dementia and other indications. This programme expands iX Biopharma’s pipeline and furthers its strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform technology to target new therapeutic areas with unmet or significant medical need.

More information can be found in the attached press release.

iX Biopharma Ltd. has reported its second half and full financial year results ended 30 June 2022.

iX Biopharma Ltd. has registered a 725% jump in revenue to S$14.39 million for its
financial year ended 30 June 2022 (“FY2022”), compared to S$1.75 million in the preceding financial year (“FY2021”). The Group also reported an adjusted EBITDA gain of S$3.02 million against an adjusted EBITDA loss of S$9.04 million in FY2021.

The unaudited interim financial statements for the second half and full year of FY2022 can be found here.

More information can be found in the attached press release.

iX Biopharma Ltd has announced the allotment and issue of 13,710,000 new ordinary shares on 21 July 2022.

More information can be found in the attached announcement.

iX Biopharma provides drug development updates for Wafermine and Wafesil.

More information can be found in the attached press release.

iX Biopharma Ltd has announced a proposed placement of 13,710,000 new ordinary shares.

More information can be found in the attached announcement.

iX Biopharma Ltd. has reported its first half results for the financial year as of 31 December 2021.

iX Biopharma Ltd. records 1H22 net profit of S$3.66M. Revenue was lifted to S$13.19M from S$0.83M in 1H21, driven by Wafermine out-licensing contribution. The balance sheet was strengthened by a cash balance of S$16.69M and another upfront fee payment of S$1.58M received in January 2022.

The unaudited interim financial statements for the first half of FY2022 can be found here.

More information can be found in the attached press release.

iX Biopharma Ltd is pleased to announce that it has entered into an agreement, through its subsidiary, with Seelos Therapeutics, Inc (“Seelos”) (Nasdaq: SEEL), a company focused on developing novel therapeutics for central nervous systems disorders.

Under the agreement, iX Biopharma Ltd will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the “Licensed Products”).

More information can be found in the attached press release.

iX Biopharma Ltd is pleased to announce that it has rolled out its game-changing SL-NAD+™, a sublingual wafer containing pure nicotinamide adenine dinucleotide (NAD+), under its Entity Health nutraceutical brand.

For the first time ever, pure and intact NAD+, also known as the molecule of youth, can be delivered directly into the bloodstream through a convenient sublingual freeze-dried wafer, without the need for invasive intravenous drips or injections. The Company leveraged its patented WaferiX sublingual drug delivery technology and proprietary freeze-drying manufacturing process to stabilise and preserve the integrity of the otherwise volatile NAD+ molecule.

More information can be found in the attached press release.

The Board of Directors of iX Biopharma Ltd. is pleased to announce that at the Annual General Meeting (AGM) of the Company held by electronic means today, all resolutions set out in the Notice of AGM dated 29 September 2021 were duly passed by way of a poll vote.

The results of AGM can be found at this link.

iX Biopharma wishes to address key questions received from the Shareholders ahead of the upcoming annual general meeting to be held on 15 October 2021.

The questions and answers can be viewed at this link.

iX Biopharma is pleased to announce that it has entered into an agreement with China Resources Pharmaceutical Commercial Group Co., Ltd (“CRPCG”) through its wholly-owned subsidiary China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (华润医 药商业集团国际贸易有限公司) for the licensing, supply, and distribution of Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction in China.

This Licensing Agreement marks the first deal between CRPCG and iX Biopharma following the execution of a strategic cooperation framework agreement announced in April 2021, to engage in an all-round cooperation including licensing and joint-venture activities in respect of iX Biopharma’s sublingual pharmaceutical and nutraceutical products in China.

More information can be found in the attached press release.

iX Biopharma Ltd has published its Annual Report for FY2021 which can be found here.

iX Biopharma Ltd has released its letter to shareholders, and other related documents, on alternative arrangements for the upcoming Annual General Meeting of the company to be held on 15 October 2021.

AGM Letter to Shareholders

Notice of AGM

AGM Proxy Form

Registration URL Link for Shareholder attendance of the AGM:
https://complete-corp.com/ix-biopharma-agm/

Email address for submission of AGM Proxy Form:
ixbiopharma-agm@complete-corp.com

Shareholders who wish to submit questions may do so via the registration website at https://complete-corp.com/ix-biopharma-agm/ or by email to
ixbiopharma-agm@complete-corp.com

iX Biopharma Ltd has reported results for the second half and full financial year ended 30 June 2021.

The fourth quarter and full financial year statements can be found here.

iX Biopharma Ltd is pleased to announce that it has entered into an agreement with medicinal cannabis company Organic Genetics Group Limited, through its wholly-owned subsidiary iX Syrinx Pty Ltd, to supply the Company’s novel sublingual medicinal cannabis wafers in New Zealand.

The supply agreement will allow iX Biopharma to access New Zealand’s pharmaceutical market through OGG’s commercial partnership with its shareholder, ANZ Pharma. ANZ Pharma is a reseller of leading pharmaceutical, health and beauty care products with an extensive distribution network of 1,108 pharmacies comprising owned and independent pharmacies, including Green Cross Health, Chemist Warehouse, and Countdown Pharmacies across the North and South Islands of New Zealand.

The agreement comes close on the heels of the Company’s shipment of Xativa to Brazil, following the product’s inclusion in the Australian Register of Therapeutic Goods (ARTG) list of drugs approved for export

More information can be found in the attached press release.

iX Biopharma’s rights issue closed on July 19 with valid acceptances and valid excess applications amounting to 196.2 per cent of the shares available for subscription. 48.8 million ordinary shares will be issued at an issue price of S$0.20 per share, to raise net proceeds of S$9.56 million.

These net proceeds will be used to fund manufacturing and marketing activities for the group’s products and for general working capital purposes.

More information can be found in the attached press release.

iX Biopharma wishes to announce that the company is exploring the possibility of a spin-off of its pharmaceutical business (including medicinal cannabis) by way of a listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “HKEX”) through Chapter 18A of the Rules Governing the Listing of Securities on the Stock Exchange.

More information can be found in the attached press release.

The Board of Directors refers to the announcement dated 30 June 2021 in relation to, amongst others, the lodgement of the offer information statement in connection with the proposed renounceable non-underwritten rights issues of up to 48,814,711 new ordinary shares in the capital of the Company (“Offer Information Statement”).

More information can be found in the attached announcement.  A copy of the Offer Information Statement can be viewed at this link.

iX Biopharma Ltd has obtained export listing status for Xativa, its CBD (cannabidiol) sublingual wafer. Xativa’s inclusion in the Australian Register of Therapeutic Goods (“ARTG”) list of drugs approved for export paves the way for the Company to expand its customer base beyond Australia in line with its plans to build itself into a global medicinal cannabis provider.

Leveraging the export listing approval, the Company will commence supply of Xativa to Brazil, where it is collaborating with its partners to distribute and market the product to doctors and patients.

More information can be found in the attached press release.

iX Biopharma is pleased to announce that it will supply its novel Wafermine sublingual ketamine wafers in a pilot study funded by Chris O’Brien Lifehouse, one of Australia’s leading comprehensive cancer hospitals in Camperdown, Sydney. The study will evaluate the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain.

More information can be found in the attached press release.

iX Biopharma Ltd is set to expand its current wafer production capacity at its manufacturing facility in Australia, following the installation and commissioning of its new freeze-dry production equipment. The expanded capacity will afford iX Biopharma the ability to pursue commercial partnerships, invest in marketing opportunities and expand into new markets.

More information can be found in the attached press release.

iX Biopharma is pleased to announce that the United States Food and Drug Administration (US FDA) has granted the Company an orphan drug designation for treatment of patients with Complex Regional Pain Syndrome (CRPS) with ketamine.

More information can be found in the attached press release.

iX Biopharma is pleased to announce it has entered into a cooperation deal with China Resources Pharmaceutical Commercial Group.

More information can be found in the attached press release.

iX Biopharma Ltd. has reported its first half results for the financial year as of 31 December 2020.

The financial statements for the period can be found here.

iX Biopharma is pleased to announce that it has received positive feedback from the European Medicines Agency (EMA) in its scientific advice to the Company regarding its Phase 3 clinical development programme for Wafermine, its sublingual ketamine wafer, for registration in Europe.

More information can be found in the attached press release.

The management of iX Biopharma presented at a guest webinar hosted by Phillip Securities.

The presentation slides can be viewed here.

iX Biopharma is pleased to announce the approval and registration of its male erectile dysfunction drug, Silcap, in Singapore

More information can be found in the attached press release.

The Board of Directors of iX Biopharma Ltd. is pleased to announce that at the Annual General Meeting (AGM) of the Company held by electronic means today, all resolutions set out in the Notice of AGM dated 1 October 2020 were duly passed by way of a poll vote.

The results of AGM can be found at this link.

A Corporate Update was also presented at the end of the AGM. The presentation slides and video recording are available here:

Corporate Update presentation slides

Link to video recording: https://youtu.be/hYNDn4Tb3uc

iX Biopharma wishes to address key questions received from the Shareholders ahead of the upcoming annual general meeting to be held on 16 October 2020.

The questions and answers can be viewed at this link.

iX Biopharma Ltd has published its Annual Report for FY2020 which can be found here.

iX Biopharma Ltd has released its letter to shareholders, and other related documents, on alternative arrangements for the upcoming Annual General Meeting of the company to held on 16 October 2020.

AGM Letter to Shareholders

Notice of AGM

AGM Proxy Form

Registration URL Link for Shareholder attendance of the AGM:
https://complete-corp.com.sg/ix-biopharma-agm/

Email address for submission of AGM Proxy Form:
ixbiopharma-agm@complete-corp.com.sg

Shareholders who wish to submit questions may do so via the registration website at https://complete-corp.com.sg/ix-biopharma-agm/ or by email to ixbiopharma-agm@complete-corp.com.sg

iX Biopharma Ltd is pleased to announce that it has secured TGA GMP license for its testing laboratory.

More information can be found in the attached press release.

iX Biopharma Ltd is pleased to announce that it has been granted a patent in Israel for its WaferiX drug delivery technology.

More information can be found in the attached press release.

iX Biopharma Ltd has announced the allotment and issue of 44,491,299 Subscription Shares on 8 September 2020.

The announcement can be found here.

The minutes for iX Biopharma’s Extraordinary General Meeting held on Friday, 4th September can be found here.

iX Biopharma Ltd has reported results of the extraordinary general meeting held on Friday, 4 September 2020 to seek shareholders’ approval for the proposed allotment and issue of 44,491,299 new ordinary shares.

The results can be found here.

iX Biopharma Ltd has reported results for the second half and full financial year ended 30 June 2020.

The fourth quarter financial statements for the period can be found here.

iX Biopharma Ltd has issued its response to address key questions received from the Shareholders ahead of the upcoming extraordinary general meeting to be held on 4 September 2020 and has provided an update of the financial effects of the proposed placement of 44,491,299 new ordinary shares.

More information on the Q&A can be found in the attached press release. The financial effects of the proposed placement can be viewed at this link.

The Directors of iX Biopharma Ltd are convening an extraordrinary general meeting of the Company to be held by way of electronic means on 4 September 2020 at 10 a.m. to seek Shareholders’ approval for the proposed allotment and issue of 44,491,299 new ordinary shares.

Letter to Shareholders

Placement Circular

EGM Proxy For

Registration URL Link for Shareholder attendance of the EGM:
https://complete-corp.com.sg/ix-biopharma-egm/

Email address for submission of EGM Proxy Form:
ixbiopharma-egm@complete-corp.com.sg

Shareholders who wish to submit questions may do so via the registration website at https://complete-corp.com.sg/ix-biopharma-egm/ or by email to ixbiopharma-egm@complete-corp.com.sg

A change in particulars of subscriber has been announced for the proposed placement of 44,491,299 new ordinary shares in the capital of iX Biopharma Ltd.

Please refer to the attachment in relation to the Change in Particulars of Subscriber.

iX Biopharma Ltd is pleased to announce the allowance of WaferiX Patent by United States Patent and Trademark Office, enhancing Wafermine Intellectual Property Protection.

More information can be found in the attached press release.

iX Biopharma Ltd has announced a proposed placement of 44,491,299 new ordinary shares.

More information can be found in the attached press release.

iX Biopharma Ltd is pleased to announce robust uptake of Xativa following its launch in Australia at the end of April 2020. Its initial production runs of approximately 1700 boxes of Xativa, a sublingual medicinal cannabidiol (“CBD”) wafer, have been fully sold.

More information can be found in the attached press release.

iX Biopharma Ltd is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application entitled “Fast Dissolving Solid Dosage Form” (U.S. Patent Application No. 13/504,309).

More information can be found in the attached press release.

iX Biopharma Ltd. is pleased to announce that it has commenced supply of Wafesil® and Silcap®, which are medicines for the treatment of male erectile dysfunction, through telemedicine in Australia.

More information can be found in the attached press release.

Read our update on impact of COVID-19 on business operations from iX Biopharma Chairman & CEO here.

iX Biopharma Group’s Xativa product, the world’s first medicinal cannabis sublingual wafer, has been featured on Channel 9 News Brisbane.

Watch the news feature here.

Read more